STRIDE Trial: Effects of Semaglutide in Patie...

The 2026 ACC/AHA Dyslipidemia Guidelines highlight that Lp(a) confers a graded ASCVD risk, with levels around 125 nmol/L (50 mg/dL) indicating meaningful risk and ~250 nmol/L (100 mg/dL) identifying a substantially higher‑risk phenotype. Coronary artery calcium scoring and hsCRP ...  Show more

ardiac and hepatic function are closely interconnected, with deterioration in one organ often accelerating disease progression in the other. Emerging evidence, including data suggesting semaglutide may slow or halt liver fibrosis progression, highlights the need to rethink how we ...  Show more

View the Show Notes Page for This Episode

<a href= "https://peterattiamd.com/subscribe/ ...

Dr. Amy Attaway and Dr. Dan Culver review the emerging relationship between COPD patients who have intermittent hypoxemia and an increase they have in co-morbidities and mortality. They discuss how multiple associative studies suggest that intermittent hypoxemia may impact muscul ...  Show more

CardioNerds Dr. Rick Ferraro, Dr. Gurleen Kaur, and Dr. Maryam Barkhordarian discuss the evidence and data supporting SGLT inhibition for cardiovascular and kidney health outcomes with expert faculty Dr. Muthu Vaduganathan. They discuss the role of SGLT inhibitors in different po ...  Show more

<h3 id="expanderHead" data-jsid="expanderHead">Story at-a-glance</h3> <div id="expanderContent" data-jsid="expanderContent"> <ul> <li><span id="bcr_rptStory_cslStory_0">Research reveals lycopene's antidepressant properties, showing it reverses stress-induced synaptic damage and e ...  Show more